From targeted quantification to untargeted metabolomics: Why LC-high-resolution-MS will become a key instrument in clinical labs

TrAC - Trends in Analytical Chemistry

Volumn 84, Issue , 2016, Pages 151-164

  Rochat, Bertrand ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Accurate mass; Clinical; High resolution; LC MS; Mass extraction window; Mass spectrometry; Orbitrap; Q Exactive; Q TOF; Quantification; Time of flight; Triple quadrupole

Indexed keywords

CHEMICAL ANALYSIS; CHEMISTRY; SPECTROSCOPY;

ACCURATE MASS; CLINICAL; HIGH RESOLUTION; LC-MS; MASS EXTRACTION; ORBITRAP; Q EXACTIVE; Q-TOF; QUANTIFICATION; TIME OF FLIGHT; TRIPLE QUADRUPOLE;

MASS SPECTROMETRY;

ANALYTIC METHOD; CLINICAL LABORATORY; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEASUREMENT ACCURACY; METABOLOMICS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RELIABILITY; REVIEW; SENSITIVITY ANALYSIS;

EID: 84959921255     PISSN: 01659936     EISSN: 18793142     Source Type: Journal    
DOI: 10.1016/j.trac.2016.02.009     Document Type: Review

References (76)

1. [1] Ramanathan, R., Jemal, M., Ramagiri, S., Humpreys, W.G., Olah, T., Korfmacher, W.A., It is time for a paradigm shift in drug discovery bioanalysis: from SRM to HRMS. J. Mass Spectrom 46 (2011), 595–601.
2. [2] Rochat, B., Quantitative/qualitative analysis using LC-HRMS: the fundamental step forward for clinical laboratories and clinical practice. Bioanalysis 4 (2012), 1709–1711.
3. [3] Josephs, J.L., HRMS: current usage, future directions and the promise of integration with unified data streams suited to post-acquisition mining. Bioanalysis 4 (2012), 471–476.
4. [4] Kaufmann, A., Butcher, P., Maden, K., Walker, S., Widmer, M., Quantitative and confirmative performance of liquid chromatography coupled to high-resolution mass spectrometry compared to tandem mass spectrometry. Rapid Commun. Mass Spectrom 25 (2011), 979–992.
5. [5] Brenton, A.G., Godfrey, A.R., Accurate mass measurement: terminology and treatment of data. J. Am. Soc. Mass Spectrom 21 (2010), 1821–1835.
6. [6] Henry, H., Sobhi, H.R., Scheibner, O., Bromirski, M., Nimkar, S.B., Rochat, B., Comparison between a high-resolution single-stage Orbitrap and a triple quadrupole mass spectrometer for quantitative analyses of drugs. Rapid Commun. Mass Spectrom 26 (2012), 499–509.
7. [7] Morin, L.P., Mess, J.N., Garofolo, F., Large-molecule quantification: sensitivity and selectivity head-to-head comparison of triple quadrupole with Q-TOF. Bioanalysis 5 (2013), 1181–1193.
8. [8] Fedorova, G., Randak, T., Lindberg, R.H., Grabic, R., Comparison of the quantitative performance of a Q-Exactive high-resolution mass spectrometer with that of a triple quadrupole tandem mass spectrometer for the analysis of illicit drugs in wastewater. Rapid Commun. Mass Spectrom 27 (2013), 1751–1762.
9. [9] Kadar, H., Veyrand, B., Antignac, J.P., Durand, S., Monteau, F., Le Bizec, B., Comparative study of low- versus high-resolution liquid chromatography-mass spectrometric strategies for measuring perfluorinated contaminants in fish. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess 28 (2011), 1261–1273.
10. [10] Grund, B., Marvin, L., Rochat, B., Quantitative performance of a quadrupole-orbitrap-MS in targeted LC-MS determinations of small molecules. J. Pharm. Biomed. Anal, 2016, 10.2016/j.jpba.2016.02.025 in press; Elsevier Ltd.
11. [11] Kaufmann, A., Butcher, P., Maden, K., Walker, S., Widmer, M., Determination of nitrofuran and chloramphenicol residues by high resolution mass spectrometry versus tandem quadrupole mass spectrometry. Anal. Chim. Acta 862 (2015), 41–52.
12. [12] Rochat, B., Kottelat, E., McMullen, J., The future key role of LC-high-resolution-MS analyses in clinical laboratories: a focus on quantification. Bioanalysis 4 (2012), 2939–2958.
13. [13] Rochat, B., Is there a future for metabotyping in clinical laboratories ?. Bioanalysis 7 (2015), 5–8.
14. [14] Gertsman, I., Gangoiti, J.A., Barshop, B.A., Validation of a dual LC-HRMS platform for clinical metabolic diagnosis in serum, bridging quantitative analysis and untargeted metabolomics. Metabolomics 10 (2014), 312–323.
15. [15] Kaufmann, A., Butcher, P., Maden, K., Walker, S., Widmer, M., Comprehensive comparison of liquid chromatography selectivity as provided by two types of liquid chromatography detectors (high resolution mass spectrometry and tandem mass spectrometry): “where is the crossover point?. Anal. Chim. Acta 673 (2010), 60–72.
16. [16] Xia, Y.Q., Lau, J., Olah, T., Jemal, M., Targeted quantitative bioanalysis in plasma using liquid chromatography/high-resolution accurate mass spectrometry: an evaluation of global selectivity as a function of mass resolving power and extraction window, with comparison of centroid and profile modes. Rapid Commun. Mass Spectrom 25 (2011), 2863–2878.
17. [17] Kellmann, M., Muenster, H., Zomer, P., Mol, J.G.J., Full scan MS in comprehensive qualitative and quantitative residue analysis in food and feed matrices: how much resolving power is required?. J. Am. Soc. Mass Spectrom 20 (2009), 1464–1476.
18. [18] Van der Heeft, E., Bolck, Y.J., Beumer, B., Nijrolder, A.W., Stolker, A.A., Nielen, M.W., Full-scan accurate mass selectivity of ultra-performance liquid chromatography combined with time-of-flight and orbitrap mass spectrometry in hormone and veterinary drug residue analysis. J. Am. Soc. Mass Spectrom 20 (2009), 451–463.
19. [19] Hopfgartner, G., Tonoli, D., Varesio, E., High-resolution mass spectrometry for integrated qualitative and quantitative analysis of pharmaceuticals in biological matrices. Anal. Bioanal. Chem 402 (2012), 2587–2596.
20. [20] Arnhard, K., Gottschall, A., Pitterl, F., Oberacher, H., Applying ‘Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass Spectra’ (SWATH) for systematic toxicological analysis with liquid chromatography-high-resolution tandem mass spectrometry. Anal. Bioanal. Chem 407 (2015), 405–414.
21. [21] Kaufmann, A., Butcher, P., Maden, K., Walker, S., Widmer, M., Reliability of veterinary drug residue confirmation: high resolution mass spectrometry versus tandem mass spectrometry. Anal. Chim. Acta 856 (2015), 54–67.
22. [22] Aceña, J., Stampachiacchiere, S., Pérez, S., Barceló, D., Advances in liquid chromatography-high-resolution mass spectrometry for quantitative and qualitative environmental analysis. Anal. Bioanal. Chem 407 (2015), 6289–6299.
23. [23] Meyer, M.R., Helfer, A.G., Maurer, H.H., Current position of high-resolution MS for drug quantification in clinical and forensic toxicology. Bioanalysis 6 (2014), 2275–2284.
24. [24] Jiwan, J.L., Wallemacq, P., Hérent, M.F., HPLC-high resolution mass spectrometry in clinical laboratory?. Clin. Biochem 44 (2011), 136–147.
25. [25] Huang, M.Q., Lin, Z.J., Weng, N., Applications of high-resolution MS in bioanalysis. Bioanalysis 5 (2013), 1269–1276.
26. [26] Bruce, S.J., Rochat, B., Béguin, A., Pesse, B., Guessous, I., Boulat, O., et al. Analysis and quantification of vitamin D metabolites in serum by ultra-performance liquid chromatography coupled to tandem mass spectrometry and high-resolution mass spectrometry – a method comparison and validation. Rapid Commun. Mass Spectrom 27 (2013), 200–206.
27. [27] Rochat, B., Peduzzi, D., McMullen, J., Favre, A., Kottelat, E., Favrat, B., et al. Validation of hepcidin quantification in plasma using LC-HRMS and discovery of a new hepcidin isoform. Bioanalysis 5 (2013), 2509–2520.
28. [28] Gepurnieks, G., Rjabova, J., Zacs, D., Bartkevics, V., The development and validation of a rapid method for the determination of antimicrobial agent residues in milk and meat using ultra performance liquid chromatography coupled to quadrupole–Orbitrap mass spectrometry. J. Pharm. Biomed. Anal 102 (2015), 184–192.
29. [29] Sundström, M., Pelander, A., Angerer, V., Hutter, M., Kneisel, S., Ojanperä, I., A high-sensitivity ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry (UHPLC-HR-TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine. Anal. Bioanal. Chem 405 (2013), 8463–8474.
30. [30] Gikas, E., Bazoti, F.N., Katsimardou, M., Anagnostopoulos, D., Papanikolaou, K., Inglezos, I., et al. Determination of colistin A and colistin B in human plasma by UPLC-ESI high resolution tandem MS: application to a pharmacokinetic study. J. Pharm. Biomed. Anal 83 (2013), 228–236.
31. [31] De Baere, S., Osselaere, A., Devreese, M., Vanhaecke, L., De Backer, P., Croubels, S., Development of a liquid-chromatography tandem mass spectrometry and ultra-high-performance liquid chromatography high-resolution mass spectrometry method for the quantitative determination of zearalenone and its major metabolites in chicken and pig plasma. Anal. Chim. Acta 756 (2012), 37–48.
32. [32] De Clercq, N., Julie, V.B., Croubels, S., Delahaut, P., Vanhaecke, L., A validated analytical method to study the long-term stability of natural and synthetic glucocorticoids in livestock urine using ultra-high performance liquid chromatography coupled to Orbitrap-high resolution mass spectrometry. J. Chromatogr. A 1301 (2013), 111–121.
33. [33] Fung, E.N., Xia, Y.Q., Aubry, A.F., Zeng, J., Olah, T., Jemal, M., Full-scan high resolution accurate mass spectrometry (HRMS) in regulated bioanalysis: LC-HRMS for the quantitation of prednisone and prednisolone in human plasma. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci 879 (2011), 2919–2927.
34. [34] Olkowicz, M., Radulska, A., Suraj, J., Kij, A., Walczak, M., Chlopicki, S., et al. Development of a sensitive, accurate and robust liquid chromatography/mass spectrometric method for profiling of angiotensin peptides in plasma and its application for atherosclerotic mice. J. Chromatogr. A 1393 (2015), 37–46.
35. [35] Zacs, D., Rjabova, J., Pugajeva, I., Nakurte, I., Viksna, A., Bartkevics, V., Ultra high performance liquid chromatography-time-of-flight high resolution mass spectrometry in the analysis of hexabromocyclododecane diastereomers: method development and comparative evaluation versus ultra high performance liquid chromatography coupled to Orbitrap high resolution mass spectrometry and triple quadrupole tandem mass spectrometry. J. Chromatogr. A 1366 (2014), 73–83.
36. [36] Dahmane, E., Boccard, J., Csajka, C., Rudaz, S., Décosterd, L., Genin, E., et al. Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology. Anal. Bioanal. Chem 406 (2014), 2627–2640.
37. [37] Vatansever, B., Lahrichi, S.L., Thiocone, A., Salluce, N., Mathieu, M., Grouzmann, E., et al. Comparison between a linear ion trap and a triple quadruple MS in the sensitive detection of large peptides at femtomole amounts on column. J. Sep. Sci 33 (2010), 2478–2488.
38. [38] Shipkova, P., Drexler, D.M., Langish, R., Smalley, J., Salyan, M.E., Sanders, M., Application of ion trap technology to liquid chromatography/mass spectrometry quantitation of large peptides. Rapid Commun. Mass Spectrom 22 (2008), 1359–1366.
39. [39] Furlong, M., Bessire, A., Song, W., Huntington, C., Groeber, E., Use of high-resolution mass spectrometry to investigate a metabolite interference during liquid chromatography/tandem mass spectrometric quantification of a small molecule in toxicokinetic study samples. Rapid Commun. Mass Spectrom 24 (2010), 1902–1910.
40. [40] Majumdar, T.K., Vedananda, S., Tse, F.L., Rapid analysis of MMI270B, an inhibitor of matrix metalloproteases in human plasma by liquid chromatography-tandem mass spectrometry: matrix interference in patient samples. Biomed. Chromatogr 18 (2004), 77–85.
41. [41] Dunand, M., Donzelli, M., Rickli, A., Hysek, C.M., Liechti, M.E., Grouzmann, E., Analytical interference of 4-hydroxy-3-methoxymethamphetamine with the measurement of plasma free normetanephrine by ultra-high pressure liquid chromatography-tandem mass spectrometry. Clin. Biochem 47 (2014), 1121–1123.
42. [42] Kumar, P., Rúbies, A., Centrich, F., Companyó, R., A false positive case due to matrix interference in the analysis of ronidazole residues in muscle tissue using LC-MS/MS. Meat Sci 97 (2014), 214–219.
43. [43] Little, J.L., Williams, A.J., Pshenichnov, A., Tkachenko, V., Identification of “known unknowns” utilizing accurate mass data and ChemSpider. J. Am. Soc. Mass Spectrom 23 (2012), 179–185.
44. [44] Commission Decision, 2002/657/EC implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results. 2002.
45. [45] Kind, T., Fiehn, O., Seven Golden Rules for heuristic filtering of molecular formulas obtained by accurate mass spectrometry. BMC Bioinform 8 (2007), 105–125.
46. [46] Zhang, H., Zhang, D., Ray, K., Zhu, M., Mass defect filter technique and its applications to drug metabolite identification by high-resolution mass spectrometry. J. Mass Spectrom 44 (2009), 999–1016.
47. [47] Friedecký, D., Mičová, K., Faber, E., Hrdá, M., Široká, J., Adam, T., Detailed study of imatinib metabolization using high-resolution mass spectrometry. J. Chromatogr. A 1409 (2015), 173–181.
48. [48] Niedenführ, S., Wiechert, W., Nöh, K., How to measure metabolic fluxes: a taxonomic guide for (13)C fluxomics. Curr. Opin. Biotechnol 34 (2015), 82–90.
49. [49] Zamboni, N., Saghatelian, A., Patti, G.J., Defining the metabolome: size, flux, and regulation. Mol. Cell 58 (2015), 699–706.
50. [50] Rochat, B., Dahmane, E., Zaman, K., Csajka, C., Improved investigations in drug safety by more in-depth individual pharmacokinetics using high-resolution mass spectrometry. Ther. Drug Monit 37 (2015), 141–146.
51. [51] Bouhifd, M., Hartung, T., Hogberg, H.T., Kleensang, A., Zhao, L., Review: toxicometabolomics. J. Appl. Toxicol 33 (2013), 1365–1383.
52. [52] Bouhifd, M., Andersen, M.E., Baghdikian, C., Boekelheide, K., Crofton, K.M., Fornace, A.J. Jr., et al. The human toxome project. ALTEX 32 (2015), 112–124.
53. [53] Kaddurah-Daouk, R., Weinshilboum, R., Pharmacometabolomics Research Network. Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine. Clin. Pharmacol. Ther, 2015, 71–75.
54. [54] Wen, B., Zhu, M., Applications of mass spectrometry in drug metabolism: 50 years of progress. Drug Metab. Rev 47 (2015), 71–87.
55. [55] Fiehn, O., Metabolomics–the link between genotypes and phenotypes. Plant Mol. Biol 48 (2002), 155–171.
56. [56] Vuckovic, D., Current trends and challenges in sample preparation for global metabolomics using liquid chromatography-mass spectrometry. Anal. Bioanal. Chem 403 (2012), 1523–1548.
57. [57] Junot, C., Fenaille, F., Colsch, B., Bécher, F., High resolution mass spectrometry based techniques at the crossroads of metabolic pathways. Mass Spectrom. Rev 33 (2014), 471–500.
58. [58] Psychogios, N., Hau, D.D., Peng, J., Guo, A.C., Mandal, R., Bouatra, S., et al. The human serum metabolome. PLoS ONE 6 (2011), 1–23 e16957.
59. [59] Dunn, W.B., Broadhurst, D., Begley, P., Zelena, E., Francis-McIntyre, S., Anderson, N., et al. Human Serum Metabolome (HUSERMET) Consortium. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc 6 (2011), 1060–1083.
60. [60] Simón-Manso, Y., Lowenthal, M.S., Kilpatrick, L.E., Sampson, M.L., Telu, K.H., Rudnick, P.A., et al. Metabolite profiling of a NIST Standard Reference Material for human plasma (SRM 1950): GC-MS, LC-MS, NMR, and clinical laboratory analyses, libraries, and web-based resources. Anal. Chem 85 (2013), 11725–11731.
61. [61] Evans, A.M., Bridgewater, B.R., Liu, Q., Mitchell, M.W., Robinson, R.J., Dai, H., High resolution mass spectrometry improves data quantity and quality as compared to unit mass resolution mass spectrometry in high-throughput profiling metabolomics. Metabolomics 4 (2014), 132–139.
62. [62] Scolamiero, E., Cozzolino, C., Albano, L., Ansalone, A., Caterino, M., Corbo, G., et al. Targeted metabolomics in the expanded newborn screening for inborn errors of metabolism. Mol. Biosyst 11 (2015), 1525–1535.
63. [63] Dénes, J., Szabó, E., Robinette, S.L., Szatmári, I., Szőnyi, L., Kreuder, J.G., et al. Metabonomics of newborn screening dried blood spot samples: a novel approach in the screening and diagnostics of inborn errors of metabolism. Anal. Chem 22 (2012), 10113–10120.
64. [64] Yuan, M., Breitkopf, S.B., Yang, X., Asara, J.M., A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat. Protoc 7 (2012), 872–881.
65. [65] Boudah, S., Olivier, M.F., Aros-Calt, S., Oliveira, L., Fenaille, F., Tabet, J.C., et al. Annotation of the human serum metabolome by coupling three liquid chromatography methods to high-resolution mass spectrometry. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci 966 (2014), 34–47.
66. [66] Hnatyshyn, S., Shipkova, P., Automated and unbiased analysis of LC-MS metabolomic data. Bioanalysis 4 (2012), 541–554.
67. [67] Johnson, C.H., Patterson, A.D., Idle, J.R., Gonzalez, F.J., Xenobiotic metabolomics: major impact on the metabolome. Annu. Rev. Pharmacol. Toxicol 52 (2012), 37–56.
68. [68] Koal, T., Deigner, H.P., Challenges in mass spectrometry based targeted metabolomics. Curr. Mol. Med 10 (2010), 216–226.
69. [69] Ramirez, T., Daneshian, M., Kamp, H., Bois, F.Y., Clench, M.R., Coen, M., et al. Metabolomics in toxicology and preclinical research. ALTEX 30 (2013), 209–225.
70. [70] Breier, M., Wahl, S., Prehn, C., Fugmann, M., Ferrari, U., Weise, M., et al. Targeted metabolomics identifies reliable and stable metabolites in human serum and plasma samples. PLoS ONE, 9, 2014, e89728.
71. [71] Ramautar, R., Berger, R., van der Greef, J., Hankemeier, T., Human metabolomics: strategies to understand biology. Curr. Opin. Chem. Biol 17 (2013), 841–846.
72. [72] Wang-Sattler, R., Yu, Z., Herder, C., Messias, A.C., Floegel, A., He, Y., et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol. Syst. Biol 8 (2012), 615–622.
73. [73] Day, A.J., Williamson, G., Biomarkers for exposure to dietary flavonoids: a review of the current evidence for identification of quercetin glycosides in plasma. Br. J. Nutr 86 (2001), 105–110.
74. [74] Farzaei, M.H., Rahimi, R., Abdollahi, M., The role of dietary polyphenols in the management of inflammatory bowel disease. Curr. Pharm. Biotechnol 16 (2015), 196–210.
75. [75] Lutz, U., Bittner, N., Ufer, M., Lutz, W.K., Quantification of cortisol and 6 beta-hydroxycortisol in human urine by LC-MS/MS, and gender-specific evaluation of the metabolic ratio as biomarker of CYP3A activity. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci 878 (2010), 97–101.
76. [76] Sottas, P.E., Vernec, A., Current implementation and future of the Athlete Biological Passport. Bioanalysis 4 (2012), 1645–1652.